Group Submits Duchenne Muscular Dystrophy Guidance, Hoping To Direct FDA Policy

Parent Project Muscular Dystrophy’s proposed guidance gives detail on biomarkers and clinical trial designs for the beleaguered field, but most importantly addresses benefit-risk assessment – which is FDA’s underlying ambition for the patient-focused drug development initiative.